Astria Therapeutics (ATXS) common stock to be removed from Nasdaq listing

Rhea-AI Filing Summary

Astria Therapeutics, Inc. is being removed from trading on the Nasdaq Stock Market LLC, as reflected in a Form 25 filing. The filing covers the company’s common stock and states that Nasdaq has followed its own rules and the SEC’s requirements under Section 12(b) of the Securities Exchange Act to strike this class of securities from listing and/or registration. Nasdaq further certifies that it has reasonable grounds to believe it meets all requirements to file this notification, and an authorized officer has signed the form on the exchange’s behalf.

Insights

Equity Markets & Listing Standards Analyst

Astria’s common stock is being removed from Nasdaq listing and registration.

Astria Therapeutics, Inc. has a Form 25 filed by the Nasdaq Stock Market LLC to remove its common stock from listing and/or registration under Section 12(b) of the Exchange Act. The document notes that Nasdaq has complied with its own rules and with 17 CFR 240.12d2-2(b), which governs exchange-initiated delisting actions.

The text also references 17 CFR 240.12d2-2(c), which addresses issuer-initiated voluntary withdrawal when applicable, indicating the regulatory paths under which such a removal can occur. The certification by an authorized Nasdaq officer formalizes that all conditions for filing Form 25 are reasonably believed to be satisfied.

Removal from a national securities exchange typically means the company’s shares would no longer trade on that exchange and may move to over-the-counter venues if trading continues. The overall impact on shareholders depends on future trading arrangements and any subsequent disclosures the company provides.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-37467

Issuer:	Astria Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	22 Boston Wharf Road, 10th Floor
	Boston	ILLINOIS	02210
Telephone number:					617-475-2423

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

common stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-01-23	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Astria Therapeutics (ATXS) Form 25 filing mean?

The Form 25 shows that the Nasdaq Stock Market LLC is removing Astria Therapeutics, Inc. common stock from listing and/or registration under Section 12(b) of the Exchange Act, after following its own rules and SEC requirements.

Which Astria Therapeutics security is affected by this Nasdaq action?

The filing states that the affected security is Astria Therapeutics, Inc. common stock, which is being removed from listing and/or registration on the Nasdaq Stock Market LLC.

Who initiated the delisting of Astria Therapeutics common stock?

The document is a Form 25 filed by the Nasdaq Stock Market LLC, certifying that it has complied with its rules and SEC Rule 12d2-2(b) for striking the class of securities from listing and/or registration.

What SEC rules are cited in the Astria Therapeutics Form 25?

The text cites 17 CFR 240.12d2-2(a), 12d2-2(b), and 12d2-2(c), which govern when and how a class of securities can be removed from listing and/or registration on a national securities exchange.

Who signed the Nasdaq certification for Astria Therapeutics’ delisting?

The certification is signed on behalf of Nasdaq Stock Market LLC by Tara Petta, identified as an AVP, as the duly authorized person for this Form 25 filing.